Galera Therapeutics, Inc. (GRTX)
USD 0.02
(8.11%)
USD 0.02
(8.11%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 46.95 Million USD | -3.83% |
| 2022 | 51.22 Million USD | -30.18% |
| 2021 | 73.36 Million USD | 3.99% |
| 2020 | 70.55 Million USD | 39.18% |
| 2019 | 50.69 Million USD | 108.99% |
| 2018 | 24.25 Million USD | 0.67% |
| 2017 | 24.09 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 4.2 Million USD | -7.86% |
| 2024 Q1 | 4.56 Million USD | -7.92% |
| 2023 Q3 | 11.08 Million USD | -34.03% |
| 2023 FY | 46.69 Million USD | -8.85% |
| 2023 Q4 | 4.96 Million USD | -55.25% |
| 2023 Q2 | 16.8 Million USD | 21.08% |
| 2023 Q1 | 13.88 Million USD | 5.49% |
| 2022 Q4 | 13.15 Million USD | 1.54% |
| 2022 Q2 | 11.95 Million USD | -9.12% |
| 2022 Q1 | 13.15 Million USD | -9.27% |
| 2022 FY | 51.22 Million USD | -30.18% |
| 2022 Q3 | 12.95 Million USD | 8.4% |
| 2021 Q2 | 21.08 Million USD | 20.63% |
| 2021 FY | 73.36 Million USD | 3.99% |
| 2021 Q3 | 20.3 Million USD | -3.74% |
| 2021 Q4 | 14.49 Million USD | -28.58% |
| 2021 Q1 | 17.48 Million USD | -7.72% |
| 2020 Q4 | 18.94 Million USD | 17.82% |
| 2020 FY | 70.55 Million USD | 39.18% |
| 2020 Q3 | 16.07 Million USD | -9.23% |
| 2020 Q2 | 17.71 Million USD | -0.59% |
| 2020 Q1 | 17.81 Million USD | 10.21% |
| 2019 Q1 | 10.39 Million USD | 17.36% |
| 2019 FY | 50.69 Million USD | 108.99% |
| 2019 Q4 | 16.16 Million USD | 25.76% |
| 2019 Q3 | 12.85 Million USD | 14.06% |
| 2019 Q2 | 11.27 Million USD | 8.42% |
| 2018 Q2 | 5 Million USD | 0.0% |
| 2018 Q1 | 5 Million USD | 0.0% |
| 2018 Q3 | 5.4 Million USD | 8.08% |
| 2018 FY | 24.25 Million USD | 0.67% |
| 2018 Q4 | 8.85 Million USD | 63.82% |
| 2017 FY | 24.09 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| America Great Health | 661.23 Thousand USD | -7000.534% |
| Ampio Pharmaceuticals, Inc. | 9.26 Million USD | -406.593% |
| Aridis Pharmaceuticals, Inc. | 29.99 Million USD | -56.54% |
| Biora Therapeutics, Inc. | 67.14 Million USD | 30.077% |
| Bio-Path Holdings, Inc. | 15.84 Million USD | -196.352% |
| Better Therapeutics, Inc. | 38.26 Million USD | -22.709% |
| Calithera Biosciences, Inc. | 40.68 Million USD | -15.39% |
| Comera Life Sciences Holdings, Inc. | 12.39 Million USD | -278.859% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 33.84 Million USD | -38.728% |
| Eloxx Pharmaceuticals, Inc. | 34.41 Million USD | -36.41% |
| Evelo Biosciences, Inc. | 108.46 Million USD | 56.714% |
| Evolutionary Genomics, Inc. | 992.8 Thousand USD | -4629.107% |
| Finch Therapeutics Group, Inc. | 32.58 Million USD | -44.07% |
| Innovation1 Biotech Inc. | 1.21 Million USD | -3765.272% |
| Kiromic BioPharma, Inc. | 19.93 Million USD | -135.47% |
| Molecular Templates, Inc. | 63.09 Million USD | 25.582% |
| Navidea Biopharmaceuticals, Inc. | 13.93 Million USD | -237.011% |
| NexImmune, Inc. | 28.16 Million USD | -66.685% |
| Orgenesis Inc. | 45.75 Million USD | -2.609% |
| Panbela Therapeutics, Inc. | 25.64 Million USD | -83.066% |
| Point of Care Nano-Technology, Inc. | 73.41 Thousand USD | -63852.0% |
| PaxMedica, Inc. Common Stock | 16.14 Million USD | -190.803% |
| Scopus BioPharma Inc. | 11.71 Million USD | -300.781% |
| Sorrento Therapeutics, Inc. | 403.56 Million USD | 88.366% |
| Statera Biopharma, Inc. | 28.82 Million USD | -62.857% |
| TRACON Pharmaceuticals, Inc. | 18.92 Million USD | -148.037% |
| Trevena, Inc. | 38.41 Million USD | -22.227% |
| Vaxxinity, Inc. | 56.05 Million USD | 16.235% |
| Vaccinex, Inc. | 23.45 Million USD | -100.175% |
| Vicapsys Life Sciences, Inc. | 1.04 Million USD | -4384.43% |
| Viracta Therapeutics, Inc. | 50.69 Million USD | 7.382% |
| ZIVO Bioscience, Inc. | 7.27 Million USD | -545.408% |